Logotipo del repositorio
 

Genetic association with intravitreal ranibizumab response for neovascular age-related macular degeneration in Hispanic population

Vista sencilla de ítem
dc.contributor.authorRodríguez, Francisco Jose
dc.contributor.authorRios, Hernan Andres
dc.contributor.authorAguilar, María Camila
dc.contributor.authorRosenstiehl, Shirley Margarita
dc.contributor.authorGelvez, Nancy
dc.contributor.authorLópez Leal, Greizy
dc.contributor.authorTamayo, Martha Lucia
dc.contributor.corporatenamePontificia Universidad Javeriana. Facultad de Medicina. Instituto de Genética Humana. Grupo de investigación Instituto de Genética Humanaspa
dc.contributor.javerianateacherGelvez, Nancy
dc.contributor.javerianateacherLópez Leal, Greizy
dc.contributor.javerianateacherTamayo, Martha Lucia
dc.coverage.cityBogotá (Colombia)spa
dc.coverage.spatialColombiaspa
dc.coverage.temporal2008-2015
dc.date.accessioned2023-03-28T19:48:39Z
dc.date.available2023-03-28T19:48:39Z
dc.date.created2019-12-13
dc.description.abstractenglishBACKGROUND/PURPOSE: Age-related macular degeneration (AMD) is the leading cause of visual impairment in patients over 55 years. Currently, the most common therapies for neovascular AMD (nAMD) are intravitreal antiangiogenics. Studies suggest that genetic factors influence on antiangiogenics therapy outcomes. The purpose of this work was to establish the association between complement factor H (CFH) (Y402H), age-related maculopathy susceptibility 2 (ARMS2) (A69S), and high-temperature requirement factor A1 (HTRA1) (rs11200638) polymorphisms and the response to treatment with ranibizumab in patients with nAMD. METHODS: A cross-sectional study with 61 eyes with nAMD treated with ranibizumab was performed. Association between polymorphisms from CFH, ARMS2, and HTRA1 with the response to treatment was established. RESULTS: The mean age of patients was 76.6 (51–91) years. Only 37.7% of patients had a functional response and 26.2% had an anatomic response. TT polymorphism Y402H from CFH gene was associated with an increased likelihood of functional response to treatment. Otherwise, there was not a statistically significant association between anatomic and functional response to gene polymorphisms rs11200638 from HTRA1 and rs10490924 from ARMS 2. CONCLUSIONS: This study suggests that the response to intravitreal antiangiogenic therapy with ranibizumab was not associated to main polymorphisms from genes HTRA1 and ARMS2. However, it was found that the response to treatment differed according to CFH genotype, suggesting that further investigations are needed to establish if patients with the CC and TC genotype may need to be monitored more closely for disease recurrence than the TT genotype.spa
dc.description.comunidadPacientes con Degeneración macularspa
dc.description.esciNospa
dc.description.indexingRevista Internacional - Indexadaspa
dc.description.orcidhttps://orcid.org/0000-0002-3925-1451spa
dc.description.orcidhttps://orcid.org/0000-0001-9380-0792spa
dc.description.orcidhttps://orcid.org/0000-0001-8297-3970spa
dc.description.publindexBspa
dc.description.quartilescopusQ3spa
dc.description.quartilewosQ4spa
dc.formatPDFspa
dc.format.mimetypeapplication/pdfspa
dc.identifierhttps://www.e-tjo.org/article.asp?issn=2211-5056;year=2019;volume=9;issue=4;spage=243;epage=248;aulast=Rodriguezspa
dc.identifier.doihttps://doi.org/10.4103/tjo.tjo_72_19spa
dc.identifier.instnameinstname:Pontificia Universidad Javerianaspa
dc.identifier.issn2211-5056 / 2211-5072 (Electrónico)spa
dc.identifier.reponamereponame:Repositorio Institucional - Pontificia Universidad Javerianaspa
dc.identifier.repourlrepourl:https://repository.javeriana.edu.cospa
dc.identifier.urihttp://hdl.handle.net/10554/63932
dc.language.isoengspa
dc.relation.citationendpage248spa
dc.relation.citationissue4spa
dc.relation.citationstartpage243spa
dc.relation.citationvolume9spa
dc.relation.ispartofjournalTaiwan Journal of Ophthalmologyspa
dc.rights.coarhttp://purl.org/coar/access_right/c_abf2spa
dc.rights.licenceAtribución-NoComercial 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by-nc/4.0/*
dc.subject.keywordAngiogenesis inhibitorsspa
dc.subject.keywordHispanic Americansspa
dc.subject.keywordMacular degenerationspa
dc.subject.keywordPolymorphismspa
dc.titleGenetic association with intravitreal ranibizumab response for neovascular age-related macular degeneration in Hispanic populationspa
dc.type.coarhttp://purl.org/coar/resource_type/c_6501spa
dc.type.hasversionhttp://purl.org/coar/version/c_ab4af688f83e57aa
dc.type.localArtículo de revistaspa

Archivos

Bloque original
Mostrando 1 - 1 de 1
Miniatura
Nombre:
Genetic association with intravitreal ranibizumab response for neovascular age-related macular degeneration in Hispanic population.pdf
Tamaño:
519.45 KB
Formato:
Adobe Portable Document Format
Descripción:
Artículo
Descargar
Bloque de licencias
Mostrando 1 - 1 de 1
No hay miniatura disponible
Nombre:
license.txt
Tamaño:
2.54 KB
Formato:
Item-specific license agreed upon to submission
Descripción:
Descargar

Colecciones

Artículos